Morningstar

Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen

Provided by Dow Jones

By Connor Hart 




  Eli Lilly received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery option for patients. 



  The pharmaceutical company said Monday that the expansion allows Zepbound to be offered in a multi-dose pen that delivers four weekly injections from a single device. The obesity treatment had previously been available in single-dose vials. 



  Eli Lilly said the drug will be available at the same self-pay price in either the multi-dose pen or single-dose vial format, starting at $299 a month for the 2.5-milligram starter dose through LillyDirect, the company's direct-to-consumer platform. 



  Zepbound is approved for chronic weight management in adults with obesity, or adults who are overweight with at least one weight-related condition. The drug is also approved to help treat moderate-to-severe obstructive sleep apnea in adults with obesity. 



  Lilly said demand for Zepbound reflects its efficacy, citing clinical trial data showing patients taking the 15-milligram dose lost an average of 20.9% of body weight over 72 weeks, compared with 3.1% for patients receiving placebo. 





  Write to Connor Hart at connor.hart@wsj.com 





  (END) Dow Jones Newswires



  February 23, 2026 09:56 ET (14:56 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
10 Best Blue-Chip Stocks to Buy for the Long Term
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
 
Even with significant growth potential, the stock’s lofty valuation is difficult to justify. 
 
 
Sean Dunlop, CFA 
 
 
 
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
 
Plus, a deep dive on SpaceX’s bid to challenge US telecoms. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
 

			Sponsor Center